title: [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
abstract: The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Júlia
authors.initials: J
authors.lastname: Gaál-Weisinger
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Orsolya
authors.initials: O
authors.lastname: Mucsi
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Gábor
authors.initials: G
authors.lastname: Körösmezey
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Balázs
authors.initials: B
authors.lastname: Szili
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Hanna
authors.initials: H
authors.lastname: Eid
authors.affiliation: I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary.
authors.forename: Richárd
authors.initials: R
authors.lastname: Kiss
authors.affiliation: I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary.
authors.forename: Csaba
authors.initials: C
authors.lastname: Bödör
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Ilona
authors.initials: I
authors.lastname: Tárkányi
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Nagy
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. demeter.judit@med.semmelweis-univ.hu.
authors.forename: Judit
authors.initials: J
authors.lastname: Demeter
mesh_terms: D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D018570:Risk Assessment
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases